Recombinant factor IX for clinical and research use

Seminars in Thrombosis and Hemostasis
Paul E Monahan, Jorge Di Paola

Abstract

The last significant advance in the therapy of hemophilia B was the introduction of recombinant factor IX (FIX), ensuring an advanced level of safety from potential infectious contaminants of plasma-derived clotting factors. Since that time, recombinant DNA techniques have been applied in research to elucidate the role of FIX and its functional domains within coagulation. At the same time, recombinant DNA technology has been applied to engineer an expanding spectrum of novel FIX therapies that are now being translating into clinical trials. The experience with the existing recombinant FIX product is reviewed with a focus on the novel products and the potential to improve the quality of life for individuals with hemophilia B.

Citations

Feb 23, 2013·Biologics : Targets & Therapy·Massimo FranchiniCarlo Bonfanti
Sep 6, 2012·Expert Opinion on Pharmacotherapy·Massimo FranchiniCarlo Bonfanti
Aug 13, 2014·Expert Review of Hematology·Massimo Franchini
Jul 26, 2011·Expert Opinion on Biological Therapy·Leonard A Valentino
Mar 21, 2012·Expert Opinion on Biological Therapy·Emmanuel J FavaloroGiuseppe Lippi
Aug 8, 2014·Expert Opinion on Emerging Drugs·Pier Mannuccio Mannucci, Massimo Franchini
May 19, 2011·Annals of Medicine·Giuseppe LippiEmmanuel J Favaloro
Mar 17, 2011·The Biochemical Journal·Charles S CraikEdwin L Madison
Jan 9, 2015·BMJ Case Reports·Sridevi B TamagondSandhyaRani Huddar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.